The effect of globalization of drug manufacturing, production, and sourcing and challenges for American drug safety

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 3, 2008, Pages 494-497

  Woo, J ^a   Wolfgang, S ^a   Batista, H ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Center for Drug Evaluation and Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE; HYPOCHOLESTEROLEMIC AGENT; LAMIVUDINE PLUS ZIDOVUDINE; OLANZAPINE; OSELTAMIVIR; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ASIA; CHINA; CONSUMER; DEVELOPING COUNTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG QUALITY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; INDIA; PRIORITY JOURNAL; REVIEW; UNITED STATES;

DRUG DESIGN; DRUG INDUSTRY; HUMANS; INTERNATIONAL COOPERATION; OUTSOURCED SERVICES; PHARMACEUTICAL PREPARATIONS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 39449128497     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100493     Document Type: Review

References (13)

1. FDA. Combating counterfeit drugs: a report of the Food and Drug Administration. 〈http://www.fda.gov/oc/initiatives/counterfeit/report02_04. html〉 (2004).
2. WHO. Counterfeit medicines. 〈http://www.who.int/mediacentre/ factsheets/fs275/en/〉 2006. Accessed November 2007.
3. FDA. Helping patients avoid counterfeit drugs over the internet. 〈http://www.accessdata.fda.gov/psn/transcript.cfm?show=67〉 (2007).
4. FDA. FDA warns consumers about counterfeit drugs from multiple internet sellers. 〈http://www.fda.gov/bbs/topics/NEWS/2007/NEW01623.html〉. 2007. Accessed November 2007.
5. FDA. FDA News Report P07-97. FDA advises consumers to avoid toothpaste from China containing harmful chemical. FDA Detains One Contaminated Shipment, Issues Import Alert 〈http://www.fda.gov/oc/opacom/hottopics/ toothpaste.html〉 (2007).
6. Steinborn, L. Guidance for industry: Q7A good manufacturing practice guidance for active pharmaceutical ingredients. 〈http://www.fda.gov/cder/ guidance/4286fnl.pdf〉 (2001). Accessed November 2007.
7. Protecting American consumers every step of the way: a strategic framework for continual improvement in import safety. A report to the President, Interagency Working Group on import safety, 〈http://www.importsafety.gov/ report/report.pdf〉 (2007).
8. Backgrounder re: RX wholesalers, Inc. v. HHS, 〈http://www.fda.gov/ cder/regulatory/PDMA/PDMA_backgrounder.pdf〉 (2006).
9. FDA. Compliance policy guides, sec. 400.210, radiofrequency identification feasibility studies and pilot programs for drugs, 〈http://www.fda.gov/ora/compliance_ref/cpg/cpgdrg/cpg400-210.html〉 (2004).
10. FDA. FDA counterfeit task force report: 2006 update 〈http://www.fda. gov/oc/initiatives/counterfeit/report6_06.html〉 2006.
11. Protecting American consumers every step of the way: a strategic framework for continual improvement in import safety. A Report to the President, Interagency Working Group on Import Safety, 〈http://www.importsafety.gov/ report/report.pdf〉 September 10, 2007.
12. World Health Organization. Good trade and distribution practices for pharmaceutical starting materials (WHO Technical Report Series, No. 917) 〈http://whqlibdoc.who.int/trs/WHO_TRS_917_annex2.pdf〉 (2003).
13. Action plan for import safety: a roadmap for continued improvement. Report to the President, Interagency Working Group on import safety, 〈http://www.importsafety.gov/report/actionplan.pdf〉 (2007).